These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 30988121)

  • 1. Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results.
    Lau AN; Thorne JC; Movahedi M; Rampakakis E; Cesta A; Li X; Couto S; Sampalis J; Bombardier C;
    J Rheumatol; 2019 Aug; 46(8):874-886. PubMed ID: 30988121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns in rheumatoid arthritis after discontinuation of methotrexate: data from the Ontario Best Practices Research Initiative (OBRI).
    Pope JE; Rampakakis E; Movahedi M; Cesta A; Li X; Couto S; Sampalis JS; Bombardier C;
    Clin Exp Rheumatol; 2018; 36(2):215-222. PubMed ID: 29148403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan.
    Tang CH; Yu F; Huang CY; Chen DY
    Int J Rheum Dis; 2019 Aug; 22(8):1544-1552. PubMed ID: 31240863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.
    Olsen IC; Lie E; Vasilescu R; Wallenstein G; Strengholt S; Kvien TK
    Rheumatology (Oxford); 2019 Mar; 58(3):481-491. PubMed ID: 30508189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of residential area on the management of rheumatoid arthritis patients initiating their first biologic DMARD: Results from the Ontario Best Practices Research Initiative (OBRI).
    Movahedi M; Joshi R; Rampakakis E; Thorne C; Cesta A; Sampalis JS; Bombardier C;
    Medicine (Baltimore); 2019 May; 98(20):e15517. PubMed ID: 31096451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study.
    Huang Y; Agarwal SK; Chen H; Chatterjee S; Johnson ML; Aparasu RR
    Clin Ther; 2023 Sep; 45(9):e177-e186. PubMed ID: 37573225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients.
    Park EH; Shin A; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
    Joint Bone Spine; 2021 Jan; 88(1):105057. PubMed ID: 32711117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies.
    Bergstra SA; Winchow LL; Murphy E; Chopra A; Salomon-Escoto K; Fonseca JE; Allaart CF; Landewé RBM
    Ann Rheum Dis; 2019 Jan; 78(1):25-30. PubMed ID: 30327328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of long-term clinical remission in rheumatoid arthritis.
    Fornaro M; Cacciapaglia F; Lopalco G; Venerito V; Iannone F
    Eur J Clin Invest; 2021 Feb; 51(2):e13363. PubMed ID: 32725883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL.
    Nicholls D; Barrett R; Button P; Truman M; Bird P; Roberts L; Tymms K; Littlejohn G; Griffiths H
    Intern Med J; 2018 Oct; 48(10):1185-1192. PubMed ID: 29968400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis.
    Fiehn C; Zinke S; Haas JS; Meise D; Theil J; Gurrath M; Orzechowski HD
    Z Rheumatol; 2023 Nov; 82(9):739-753. PubMed ID: 36757417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Characteristics and Cytokine Profiles of Organizing Pneumonia in Patients with Rheumatoid Arthritis Treated with or without Biologics.
    Kawasumi H; Gono T; Tanaka E; Kaneko H; Kawaguchi Y; Yamanaka H
    J Rheumatol; 2016 Apr; 43(4):738-44. PubMed ID: 26834212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study.
    Dormuth CR; Fisher A; Hudson M; Austin PC; Ernst P; Bresee L; Chateau D; Tamim H; Paterson JM; Lafrance JP; Taylor-Gjevre RM; Platt RW; Canadian Network For Observational Drug Effect Studies Cnodes Investigators
    Semin Arthritis Rheum; 2021 Dec; 51(6):1291-1299. PubMed ID: 34462128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study.
    Yoshida K; Radner H; Mjaavatten MD; Greenberg JD; Kavanaugh A; Kishimoto M; Matsui K; Okada M; Reed G; Saeki Y; Tohma S; Kremer J; Solomon DH
    J Rheumatol; 2015 Dec; 42(12):2238-46. PubMed ID: 26523025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis.
    Lechtenboehmer CA; Burkard T; Reichenbach S; Walker UA; Burden AM; Hügle T
    Arthritis Res Ther; 2021 Oct; 23(1):267. PubMed ID: 34702319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
    Choy E; Aletaha D; Behrens F; Finckh A; Gomez-Reino J; Gottenberg JE; Schuch F; Rubbert-Roth A
    Rheumatology (Oxford); 2017 May; 56(5):689-697. PubMed ID: 27550301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
    Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose tapering of biologic agents in patients with rheumatoid arthritis-results from a cohort study in Germany.
    Krause D; Krause C; Rudolf H; Baraliakos X; Braun J; Schmitz E
    Clin Rheumatol; 2021 Mar; 40(3):887-893. PubMed ID: 32822057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity in Patient Characteristics and Differences in Treatment Across 4 Canadian Rheumatoid Arthritis Cohorts.
    Hazlewood GS; Bombardier C; Li X; Movahedi M; Choquette D; Coupal L; Bykerk VP; Schieir O; Mosher D; Marshall DA; Bernatsky S; Spencer N; Richards DP; Proulx L; Barber CEH;
    J Rheumatol; 2022 Jan; 49(1):16-25. PubMed ID: 34334357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.